5-Fluorouracil for Pediatric DCR

In this interview from ASOPRS 2020, Dr. Alon Kahana discusses the use of 5-fluorouracil (5-FU) injection during pediatric dacryocystorhinostomy (DCR). He explained that 16% of the 20 study patients experienced recurrence of nasolacrimal duct obstruction after DCR, but that none of these events occurred in patients who received 5-FU. Unlike mitomycin C, 5-FU does not cause cell death, mitigating risk of necrotic and avascular complications. Dr. Kahana believes there are essentially no risks with 5-FU; he has been following these patients for years and has not observed any negative effects on development or scarring.

Relevant Financial Disclosures: None